Hyperlipoproteinemia Type I: Clinical Trials

2 trials for Hyperlipoproteinemia Type I, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 12Completed 2
Phase 21Completed 1

Follow Hyperlipoproteinemia Type I: new trials by email Literature Review of Hyperlipoproteinemia Type I trials Research Report on Hyperlipoproteinemia Type I

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS)
ARO-APOC3, sterile normal saline (0.9% NaCl) - Hypertriglyceridemia, Familial Chylomicronemia
Phase 1CompletedArrowhead Pharmaceuticals1122019-03-082025-12-24
Safety, Tolerability,Pharmacokinetics(PK)and Pharmacodynamics(PD)Assessment of LCQ908 in Patients With Severe Hypertriglyceridemia
LCQ908, Placebo - Hyperlipoproteinemia
Phase 1 / Phase 2CompletedNovartis Pharmaceuticals82010-05-012020-12-17

Narrower conditions

Hypertriglyceridemia (2)  ·  Hyperlipoproteinemias (1)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2)  ·  Dyslipidemias (2)  ·  Genetic Diseases, Inborn (2)  ·  Hyperlipidemias (2)  ·  Lipid Metabolism Disorders (2)  ·  Lipid Metabolism, Inborn Errors (2)  ·  Metabolic Diseases (2)  ·  Metabolism, Inborn Errors (2)  ·  Nutritional and Metabolic Diseases (2)  ·  Hyperlipoproteinemias (1)

Interventions

pradigastat (1)

Sponsors

Arrowhead Pharmaceuticals (1)  ·  Novartis Pharmaceuticals (1)

Countries

Canada (2)  ·  Australia (1)  ·  New Zealand (1)

Results publications

PMID 25889044, PMID 38320498